[go: up one dir, main page]

AU2001255398A1 - Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor - Google Patents

Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor

Info

Publication number
AU2001255398A1
AU2001255398A1 AU2001255398A AU5539801A AU2001255398A1 AU 2001255398 A1 AU2001255398 A1 AU 2001255398A1 AU 2001255398 A AU2001255398 A AU 2001255398A AU 5539801 A AU5539801 A AU 5539801A AU 2001255398 A1 AU2001255398 A1 AU 2001255398A1
Authority
AU
Australia
Prior art keywords
ctla
antibodies
bind
antigen binding
binding portions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001255398A
Inventor
Jeffrey A Bluestone
Mary Collins
Matthew Griffin
David Kranz
Matthew Whitters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
University of Illinois System
Original Assignee
Genetics Institute LLC
University of Illinois at Urbana Champaign
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC, University of Illinois at Urbana Champaign, University of Illinois System filed Critical Genetics Institute LLC
Publication of AU2001255398A1 publication Critical patent/AU2001255398A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001255398A 2000-04-12 2001-04-12 Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor Abandoned AU2001255398A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19685100P 2000-04-12 2000-04-12
US60/196,851 2000-04-12
PCT/US2001/012275 WO2001079300A1 (en) 2000-04-12 2001-04-12 Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor

Publications (1)

Publication Number Publication Date
AU2001255398A1 true AU2001255398A1 (en) 2001-10-30

Family

ID=22727032

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001255398A Abandoned AU2001255398A1 (en) 2000-04-12 2001-04-12 Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor

Country Status (4)

Country Link
US (1) US20030086932A1 (en)
EP (1) EP1274733A1 (en)
AU (1) AU2001255398A1 (en)
WO (1) WO2001079300A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120034155A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
GB0903325D0 (en) * 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
WO2016196237A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
MA50949B1 (en) 2016-12-07 2023-12-29 Memorial Sloan Kettering Cancer Center ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
CA3120619A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
FR2695563B1 (en) * 1992-09-11 1994-12-02 Pasteur Institut Microparticles carrying antigens and their use for the induction of humoral or cellular responses.
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression

Also Published As

Publication number Publication date
WO2001079300A9 (en) 2002-12-27
WO2001079300A1 (en) 2001-10-25
US20030086932A1 (en) 2003-05-08
EP1274733A1 (en) 2003-01-15

Similar Documents

Publication Publication Date Title
AU2001264946A1 (en) Bispecific immunoglobulin-like antigen binding proteins and method of production
AU2002327704A1 (en) Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
WO2002016401A3 (en) Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof
AU2002326531A1 (en) Monoclonal antibodies to activated erbb family members and methods of use thereof
AU2001268855A1 (en) Single-domain antigen-binding antibody fragments derived from llama antibodies
AU4643596A (en) Chimeric antibodies comprising antigen binding sites and b and t cell epitopes
AU2559799A (en) Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
WO2002030986A3 (en) HUMANIZED ANTI-LT-β-R ANTIBODIES
AU3041100A (en) Binding of antibody fragments to solid supports
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
GB0029360D0 (en) Humanised antibodies and uses thereof
AU2001255398A1 (en) Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor
AU2001290315A1 (en) Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
EP1581096A4 (en) Antigen pipa and antibodies that bind thereto
AU2003218456A1 (en) Antibodies that specifically bind to gmad
AU7072998A (en) Immunoassays using anti-allotypic monoclonal antibodies
AU1190101A (en) Engineering antibodies that bind irreversibly
AU2003275834A1 (en) ANTIBODIES THAT BIND alphaE INTEGRIN
HUP0001808A3 (en) Antibodies that bind to the nidogen-binding domain of laminin, their production and use
AU2596397A (en) Monoclonal antibody that detects apoptotic antigen
AU2759899A (en) Purified sperm surface antigen, monoclonal antibody therefor and application therefor
WO1999028465A3 (en) Pias molecules that recognize and bind stat proteins and uses thereof
AU2002365272A1 (en) Epsilon immunoglobulin chain derived peptides for induction of anti-ige antibodies
AU6068000A (en) Peptide ligands that bind igm antibodies and block interaction with antigen
AU2001249546A1 (en) Methods for treating disease with antibodies to cxcr3